Artal Group S.A. Verve Therapeutics, Inc. Transaction History

Artal Group S.A.

  • $214 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
SELL
$17.85 - $40.7 $1.79 Million - $4.07 Million
-100,000 Reduced 25.0%
300,000 $5.81 Million
Q3 2021

Nov 12, 2021
SELL
$46.0 - $73.99 $4.6 Million - $7.4 Million
-100,000 Reduced 20.0%
400,000 $18.8 Million
Q2 2021

Aug 13, 2021
BUY
$31.92 - $60.25 $16 Million - $30.1 Million
500,000 New
500,000 $30.1 Million

Others Institutions Holding VERV

# of Institutions
186
Shares Held
73.3M
Call Options Held
85K
Put Options Held
215K
View Full List

About Verve Therapeutics, Inc.

VERV Quotes by TradingView
  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $317M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email